Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation.
about
Management of immunosuppressant agents following liver transplantation: Less is moreDe novo glomerular diseases after renal transplantationHalofuginone Synergistically Enhances Anti-Proliferation of Rapamycin in T Cells and Reduces Cytotoxicity of Cyclosporine in Cultured Renal Tubular Epithelial CellsThe pros and the cons of mTOR inhibitors in kidney transplantation.Systemic meta-analysis assessing the short term applicability of early conversion to mammalian target of rapamycin inhibitors in kidney transplant.Multiple indications for everolimus after liver transplantation in current clinical practice.Immunosuppressive Medications.A 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic riskMammalian target of rapamycin complex 1 (mTORC1) Is required for mouse spermatogonial differentiation in vivo.Lung transplantation: a treatment option in end-stage lung disease.Diverse interventions that extend mouse lifespan suppress shared age-associated epigenetic changes at critical gene regulatory regionsEverolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.Interstitial Lung Disease Associated with mTOR Inhibitors in Solid Organ Transplant Recipients: Results from a Large Phase III Clinical Trial Program of Everolimus and Review of the Literature.Everolimus and sirolimus in transplantation-related but different.Immunosuppressive minimization with mTOR inhibitors and belatacept.The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient.Kidney transplantation, bioengineering and regeneration: an originally immunology-based discipline destined to transition towards ad hoc organ manufacturing and repair.Safety of mTOR inhibitors in adult solid organ transplantation.Differential influence of tacrolimus and sirolimus on mitochondrial-dependent signaling for apoptosis in pancreatic cells.Practical considerations for the use of mTOR inhibitors.Incidence and outcome of BK polyomavirus infection in a multicenter randomized controlled trial with renal transplant patients receiving cyclosporine-, mycophenolate sodium-, or everolimus-based low-dose immunosuppressive therapy.Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.Short-term outcome and quality of life in kidney transplant recipient with monoclonal gammopathy.An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.High-dose calcineurin inhibitor-free everolimus as a maintenance regimen for heart transplantation may be a risk factor for Pneumocystis pneumonia.Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled TrialPilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term OutcomesConversion to a sirolimus-based regimen is associated with lower incidence of BK viremia in low-risk kidney transplant recipients.Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition.Long-term outcomes following sirolimus conversion after renal transplantation.A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimusRegulation of human T cell responses by dNP2-ctCTLA-4 inhibits human skin and microvessel graft rejection
P2860
Q26770033-1B9E11DE-987A-4624-B0EC-AE01B8780A4FQ27005877-DADA6696-BE65-4AFA-833D-7B6C56051919Q28551630-D612FF3F-0FCB-4564-8582-0F9639827C99Q33412367-0A300219-CD37-4694-B5FD-49A306889373Q33617408-1B875830-401D-49B3-9282-2A9203CC3F1AQ33891730-3662D9E4-2BD0-4197-8138-D033FDEB3DF0Q34484801-4ECD0D89-0B65-4ED6-AC13-D8CE18C3108CQ35649082-99A2FFFE-3972-4120-8F47-6360AD407EC3Q36271477-0F39EE72-D5ED-4B80-8A81-82463DE230ADQ37642300-F4332BF8-3C46-4157-B32F-5C0BAE03E34CQ37726297-D815E442-B504-476D-ACE8-FFB2D497D2EAQ38229930-4641D837-6BC4-4A53-AB82-BA5246733302Q38314899-38E838F8-D86A-4140-9670-9A4870E56AC5Q38442560-3C3C31FD-0993-43E8-A9C1-09A105E3D494Q38470256-59AC7551-C75F-4955-9DBE-407F353D75B9Q38585232-3DDD98A7-E5E0-47B5-9D72-6B4CFE54FAC7Q38658621-643636D3-758C-4A1D-ADCE-7E3A7C9A5529Q38669190-BCE52BD9-D805-4D1A-A932-F7CC835DC1B4Q38762229-721E2CF0-EA7A-4552-8A69-E5DEBA26CECAQ38863078-F9DBD57A-6BB8-46EF-BE63-C3E1A1BED787Q38930188-9F262120-BFAE-44A5-9B48-7564BB964CE1Q38947867-172C8CFB-0BD4-4CE4-8C7F-EA69C227A0A5Q39012988-3BF494DF-47D2-4207-AA43-5E6171333C04Q40210857-CFE7D741-C5FB-4301-AA24-7265877BA1DCQ40220124-907FB9B1-699A-4F72-9FAD-69A1163E492DQ40235213-3962397E-ACBD-42E0-B851-6E5DFCBD6B7AQ40567804-CF84B8B9-4549-45AB-B4F5-F6344332CEB2Q40907143-3158DA57-65ED-4447-A54C-38108B8EC5ACQ41313340-E3CD906F-2FCE-4A19-BBB8-7508F6E408D2Q41548443-D5F2E29F-9631-4E92-8E2A-9C79DEC0ED70Q42718504-803E5E9D-66E6-49AD-B107-85C0EE2B7498Q44544352-5CB7091B-EDA3-40ED-8264-0444D884E105Q56035477-1C415F74-2958-4600-B0F9-2C1C921A0E9EQ56871235-01E35058-70F7-4176-A93F-4CED96C02F4E
P2860
Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Review of combination therapy ...... ization after transplantation.
@en
type
label
Review of combination therapy ...... ization after transplantation.
@en
prefLabel
Review of combination therapy ...... ization after transplantation.
@en
P2093
P1476
Review of combination therapy ...... ization after transplantation.
@en
P2093
Alexander Wiseman
Douglas Slakey
Kenneth Chavin
V Ram Peddi
P304
P356
10.1016/J.TRRE.2013.06.001
P577
2013-08-08T00:00:00Z